R Mehta

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
  2. doi request reprint Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012

Collaborators

  • K Blake
  • L Hendeles
  • R L Kunka
  • T Spencer

Detail Information

Publications2

  1. pmc Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
    Rashmi Mehta
    Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 8:159-67. 2013
    ....
  2. doi request reprint Bioavailability of inhaled fluticasone propionate via chambers/masks in young children
    K Blake
    Center for Pharmacogenomics and Translational Research, Dept of Biomedical Research, Nemours Children s Clinic, Jacksonville, FL, USA
    Eur Respir J 39:97-103. 2012
    ..VHCs are not interchangeable, as differences in drug delivery to the lung may occur. A population pharmacokinetic approach can be used to determine lung bioavailability of FP...